A look at using best practice tech transfer methods for CGTs to increase process and analytics robustness while being scalable.
Matthew Hewitt
Advertisement
Matthew Hewitt is vice-president, technical officer, Cell & Gene Therapy & Biologics at Charles River Laboratories.
Articles by Matthew Hewitt
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Nuravax Alzheimer Vaccine AV-1959R Earns FDA Fast Track Designation
2
Nano24's Inhaled EXO-CD24 Cuts ARDS Mortality in Phase 2b Trial
3
METiS TechBio, Lilly Partner on AI-Designed LNPs for Tissue-Specific Delivery
4
The BioPharm Brief: Lung Injury Survival, Alzheimer Prevention, and Longer Dosing Intervals
5